Position in JNJ
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$103,619,760
+$67,442,640 QoQ
Shares Held
408,000
+175.7% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.61%
of 13F equity value
Holder Rank
#295
of 4,676 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FARALLON CAPITAL MANAGEMENT LLC holds $435,817,620 across 6 Drug Manufacturers - General names. JNJ ranks #3 (23.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NVO |
Novo Nordisk A S
|
2,619,000 | $125,554,860 | |
| 2 | AZN |
Astrazeneca PLC
|
574,000 | $108,841,880 | |
| 3 | JNJ |
Johnson & Johnson
This page
|
408,000 | $103,619,760 | |
| 4 | NVS |
Novartis AG
|
363,000 | $56,889,360 | |
| 5 | MRK |
Merck & Co., Inc.
|
199,000 | $25,571,500 | |
| 6 | BIIB |
Biogen Inc.
|
71,000 | $15,340,260 |
All Filings in JNJ
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $103,619,760 | 408,000 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $36,177,120 | 148,000 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||